Research programme: viral replication inhibitors - Novita Healthcare/CSIRO
Latest Information Update: 04 Nov 2017
At a glance
- Originator Avexa; CSIRO
- Developer CSIRO; Novita Healthcare
- Class
- Mechanism of Action Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Viral infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Viral-infections in Australia
- 31 Dec 2006 This collaboration is still active
- 09 Nov 2005 Preclinical trials in Viral infections in Australia (unspecified route)